MENU

Elizabeth Plimack Appointed Chair of Scientific Advisory Board for Bladder Cancer Advocacy Network

January 20, 2021

Elizabeth Plimack, MD, MS, chair of the Scientific Advisory Board (SAB) for BCANElizabeth Plimack, MD, MS, chair of the Scientific Advisory Board (SAB) for BCAN

PHILADELPHIA (January 19, 2021)—Elizabeth Plimack, MD, MS, professor in the Department of Hematology/Oncology and chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center, has been appointed chair of the Scientific Advisory Board (SAB) for the Bladder Cancer Advocacy Network (BCAN).

“It has been an honor to serve BCAN over the last decade, and I am excited to take on this new role as chair of the Scientific Advisory Board. We are fortunate in the field of bladder cancer to have created a culture of engagement and collaboration—for which BCAN as an organization deserves credit,” said Plimack.

“I look forward to working with my fellow experts toward the shared goals of better understanding this disease and improving outcomes for our patients through science,” she added.

Plimack’s work at Fox Chase focuses on the treatment of kidney, bladder, prostate, and testicular cancer. Her research looks at identifying biomarkers in neoadjuvant cisplatin-based chemotherapy in bladder cancer, as well as developmental therapeutics and immunotherapy in genitourinary malignancies.

“We are pleased that Dr. Plimack has agreed to serve as the new chairperson of our SAB. We welcome her leadership and strategic guidance on medical and clinical issues and also to ensure that BCAN’s programs and products are up-to-date, accurate, and impartial,” said Andrea Maddox-Smith, CEO of BCAN. Plimack will succeed Gary D. Steinberg, MD, FACS, of NYU Langone Cancer Center in New York, who served as chair of the SAB for 11 years.

In addition to her other roles at Fox Chase, Plimack is also an elected member of the Board of Directors of the American Society for Clinical Oncology and an advisor to the Society of Urologic Oncology Clinical Trials Consortium. She also serves on multiple clinical trial steering and safety monitoring committees as well as the National Comprehensive Cancer Network guideline panels for bladder cancer and kidney cancer.

BCAN is the only national advocacy organization dedicated to advancing bladder cancer care and research. The group works with medical professionals and the community to provide information and resources to individuals with bladder cancer. BCAN’s SAB includes leading academic urologists, oncologists, radiation oncologists, and pathologists working within the bladder cancer field. These leaders have made strides in their fields and represent many of the major cancer centers in the United States and Canada.

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

 

For more information, call 888-369-2427

Connect with Fox Chase